Also trades as: IN.TO (TSX) · $vol 0M
INM NASDAQ
InMed Pharmaceuticals Inc.
1W: -3.6%
1M: -1.5%
3M: -17.4%
YTD: +18.8%
1Y: -40.1%
3Y: -90.6%
5Y: -99.8%
$1.33
-0.02 (-1.48%)
Weekly Expected Move ±5.8%
$1
$1
$1
$1
$1
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$3.2B
+64167.3% ▲
Gross Profit
$710M
+41494.3% ▲
Operating Income
-$10M
-25.0% ▼
Net Income
-$13M
-53.9% ▼
EPS (Diluted)
$-3.12
+62.7% ▲
EBITDA
-$9M
-26.6% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $1M | $4M | $5M | $5M | $3.2B |
| YoY Growth | +0.0% | +290.6% | +14.8% | +7.5% | +64167.3% |
| Cost of Revenue | $546K | $3M | $3M | $3M | $2.5B |
| Gross Profit | $544K | $1M | $1M | $2M | $710M |
| Gross Margin | 49.9% | 33.9% | 23.9% | 34.5% | 22.3% |
| R&D Expenses | $7M | $4M | $3M | $3M | $15M |
| SG&A Expenses | $7M | $6M | $6M | $7M | $1.9B |
| Operating Expenses | $14M | $10M | $9M | $10M | $9M |
| Operating Income | -$14M | -$8M | -$8M | -$8M | -$10M |
| Operating Margin | -1266.0% | -202.6% | -176.9% | -160.2% | -0.3% |
| Interest Expense | $0 | $0 | $0 | $373K | $11K |
| Income Before Tax | -$19M | -$8M | -$8M | -$8M | -$11M |
| Tax Expense | $0 | $13K | $7K | $0 | $0 |
| Net Income | -$19M | -$8M | -$8M | -$8M | -$13M |
| Net Margin | -1707.3% | -192.2% | -166.9% | -165.1% | -0.4% |
| EPS (Diluted) | $-21350.51 | $-86.00 | $-27.55 | $-11.44 | $-3.12 |
| EBITDA | -$13M | -$8M | -$7M | -$7M | -$9M |
| Shares Outstanding | 1121 | 122422 | 381053 | 975985 | 4M |